Synta Rises on Potential for Novel Cancer Drug: Boston Mover

Synta Pharmaceuticals Corp. gained the most in 20 months in anticipation of study results that may help pave the way for broader use of its experimental lung cancer compound ganetespib.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.